An analysis of data from coronaviruses vaccines suggests the vaccine’s effectiveness in reducing the spread of avian influenza has been greatly exceeded, the U.S. Centers for Disease Control and Prevention said Monday.
The agency also found that people who received two doses of coronajet, or the second dose in about 80 percent of cases, were more likely to have a milder illness than those who received the first dose.
The vaccine was first approved in 2004 for use in the U, D.C., area.
In that year, coronaviral infection killed more than 11,000 people, the CDC reported.
The CDC said it was aware of no deaths linked to the vaccine.
But it cautioned that the data does not prove that the vaccine was as effective as it is often touted.
The virus continues to pose a health risk to people who have been exposed to it.
“We cannot be certain that the two doses were equally effective.
We cannot say that it was the best option,” CDC Director Tom Frieden said in a statement.
“But based on the available data, we can confidently say that the coronavirots vaccine is a good option.”
The first doses of the vaccine were administered to people between the ages of 4 and 6 years old.
The second dose was administered to children 6 to 17 years old and was approved for use at ages 14 and 17.
The two vaccines are manufactured by Pfizer Inc., which makes the Avian flu vaccine and Pfizer Vaccines.
Pfizer did not immediately respond to a request for comment.
Frieden’s remarks came as more than 1,000 coronavids infections were reported nationwide Monday, according to the CDC.
More than 11 million people have been vaccinated with the first coronavivirus vaccine and about 590,000 have received the second.
The other two vaccines, Gardasil and Cervarix, were first approved for vaccine use in 2012.
The first coronajets were given to people under age 16 years old, with the second given to older adults, the vaccine companies said.
The vaccines have been used for several years to reduce the spread and death of coronas, the most common respiratory disease in the United States.
But they were not widely used when coronavid outbreaks were increasing, Frieden told reporters at the CDC’s news conference.